Anna Richo Net Worth

The estimated Net Worth of Anna Richo is at least $1.8 Millón dollars as of 1 August 2012. Ms. Richo owns over 5,125 units of Adamas Pharmaceuticals Inc stock worth over $345,174 and over the last 16 years she sold ADMS stock worth over $1,459,605. In addition, she makes $0 as Director at Adamas Pharmaceuticals Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Ms. Richo ADMS stock SEC Form 4 insiders trading

Anna has made over 6 trades of the Adamas Pharmaceuticals Inc stock since 2011, according to the Form 4 filled with the SEC. Most recently she exercised 5,125 units of ADMS stock worth $320,979 on 1 August 2012.

The largest trade she's ever made was exercising 46,446 units of Adamas Pharmaceuticals Inc stock on 27 January 2012 worth over $2,831,348. On average, Anna trades about 2,791 units every 9 days since 2008. As of 1 August 2012 she still owns at least 41,992 units of Adamas Pharmaceuticals Inc stock.

You can see the complete history of Ms. Richo stock trades at the bottom of the page.

Anna Richo biography

Anna S. Richo J.D. serves as Director of the Company. Ms. Richo's successful career path includes leadership roles in biotechnology and pharmaceutical companies as general counsel and leading compliance, intellectual property, and corporate litigation. Ms. Richo has previously been recognized as one of the 'Top 15 Women in Pharma'. She holds a bachelor's degree in industrial and labor relations from Cornell University and a J.D. degree from DePaul University, College of Law. She is a member of the Board of Trustees for DePaul University.

How old is Anna Richo?

Anna Richo is 60, she's been the Director of Adamas Pharmaceuticals Inc since 2020. There are 5 older and 7 younger executives at Adamas Pharmaceuticals Inc. The oldest executive at Adamas Pharmaceuticals Inc is Ivan Lieberburg, 70, who is the Independent Director.

What's Anna Richo's mailing address?

Anna's mailing address filed with the SEC is 10 S DEARBORN STREET, 54TH FLOOR, CHICAGO, IL, 60603.

Insiders trading at Adamas Pharmaceuticals Inc

Over the last 11 years, insiders at Adamas Pharmaceuticals Inc have traded over $26,222,162 worth of Adamas Pharmaceuticals Inc stock and bought 1,128,061 units worth $17,799,399 . The most active insiders traders include Point Partners Llcjay Jeffr..., David L Mahoney y William W. Ericson. On average, Adamas Pharmaceuticals Inc executives and independent directors trade stock every 25 days with the average trade being worth of $254,236. The most recent stock trade was executed by Vijay Shreedhar on 21 June 2021, trading 6,200 units of ADMS stock currently worth $31,992.

What does Adamas Pharmaceuticals Inc do?

Adamas Pharmaceuticals Inc. delivers innovative medicines that reduce the burden of neurological diseases on patients, caregivers and society. The company is a fully integrated company focused on growing a portfolio of therapies to address a range of neurological diseases.

Complete history of Ms. Richo stock trades at Adamas Pharmaceuticals Inc, AMGEN, Illumina Inc y Exelon

Adamas Pharmaceuticals Inc executives and stock owners

Adamas Pharmaceuticals Inc executives and other stock owners filed with the SEC include:

• Neil McFarlane,
  Chief Executive Officer, Director
• Vijay Shreedhar,
  Chief Commercial Officer
• Christopher Prentiss,
  Chief Financial Officer, Chief Accounting Officer, Principal Financial Officer and Principal Accounting Officer
• David Mahoney,
  Lead Independent Chairman of the Board
• Martha Demski,
  Independent Director
• William Ericson,
  Independent Director
• Michael Bigham,
  Independent Director
• Mardi Dier,
  Independent Director
• Ivan Lieberburg,
  Independent Director
• John MacPhee,
  Director
• Anna Richo,
  Director
• Adrian Quartel,
  Chief Medical Officer
• Adrian Quartel M.D.,
  Chief Medical Officer
• Eric C. Schlezinger,
  Head of HR
• Dr. Jill M. Jene,
  Head of Corp. Devel., Strategy , Portfolio Planning & Alliance Management
• Sarah Mathieson,
  Head of Corp. Communications, Patient Advocacy & Engagement
• Richard H Booth,
  Director
• Rajiv Patni,
  Chief Medical Officer
• Ix Lp Seventh Mdv Partners,...,
  
• William J Dawson,
  Chief Financial Officer
• Natalie Mc Clure,
  SVP, Product Development
• Point Partners Llcjay Jeffr...,
  
• Richard King,
  Chief Operating Officer
• Gregory T Went,
  Chief Executive Officer
• Alfred G Merriweather,
  Chief Financial Officer
• Jennifer J Rhodes,
  General Counsel
• Capital Equity Investments,...,
  10% owner
• Sara Grootwassink Lewis,
  Director
• Jeffrey H Knapp,
  Chief Operating Officer
• Grace Shin,
  General Counsel
• Vii Lpmdv Ix Lp Seventh Mdv...,
  
• Ventures Management Iii, Ll...,
  
• Spyros Papapetropoulos,
  Director